524768 — Emmessar Biotech and Nutrition Income Statement
0.000.00%
- IN₹138.89m
- IN₹67.48m
- IN₹6.11m
Annual income statement for Emmessar Biotech and Nutrition, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | R2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | PRESS | PRESS |
Standards: | IAS | IAS | IAS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 69.9 | 3.65 | 10.2 | 5.55 | 6.11 |
Cost of Revenue | |||||
Gross Profit | 34.6 | 2.39 | 6.19 | 3.57 | 4.29 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 62 | 13.5 | 18 | 17.3 | 16.6 |
Operating Profit | 7.89 | -9.87 | -7.84 | -11.8 | -10.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 22.5 | 9.31 | 9.67 | 8.13 | 9.58 |
Provision for Income Taxes | |||||
Net Income After Taxes | 14.5 | 4.75 | 5.04 | 6.51 | 3.16 |
Net Income Before Extraordinary Items | |||||
Net Income | 14.5 | 4.75 | 5.04 | 6.51 | 3.16 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14.5 | 4.75 | 5.04 | 6.51 | 3.16 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.9 | 0.951 | 1.01 | 1.28 | 0.61 |
Dividends per Share |